ライフサイエンスコーパス: Hippo pathway

1 stions in the regulation and function of the Hippo pathway.

2 ion suggests TAZ to be a redox sensor of the Hippo pathway.

3 r accumulation of YAP, a key mediator of the Hippo pathway.

4 TS2 tumor suppressor is a core member of the Hippo pathway.

5 a major transcriptional co-activator of the Hippo pathway.

6 s another upstream negative regulator of the Hippo pathway.

7 ctivator yes-associated protein (YAP) in the Hippo pathway.

8 size independently of proliferation and the Hippo pathway.

9 tablish MAP4Ks as components of the expanded Hippo pathway.

10 eutic via the mechanotransduction arm of the Hippo pathway.

11 he major effector of and is inhibited by the Hippo pathway.

12 d inhibit YAP/TAZ, the main effectors of the Hippo pathway.

13 tly of phospholipase Cbeta and the canonical Hippo pathway.

14 estigated the interactions of d-Csk with the Hippo pathway.

15 hat mediates the biological functions of the Hippo pathway.

16 protein TAZ are downstream effectors of the Hippo pathway.

17 n of CD31 and VE-cadherin expression and the Hippo pathway.

18 kie, a transcription factor regulated by the Hippo pathway.

19 e regulation and biological functions of the Hippo pathway.

20 rylated YAP on five sites independent of the Hippo pathway.

21 tact inhibition of proliferation through the Hippo pathway.

22 ub, a negative regulator of Warts within the Hippo pathway.

23 echanism that is distinct from the canonical Hippo pathway.

24 bryonic and MaSC signatures and activate the Hippo pathway.

25 factors are the most distal effectors of the Hippo pathway.

26 olved in tumorigenesis and regulation of the Hippo pathway.

27 LIM proteins are negative regulators of the Hippo pathway.

28 imultaneous deregulation of both the Ras and Hippo pathways.

29 The Hippo pathway, a conserved kinase cascade, inhibits card

30 The Hippo pathway, a kinase cascade that prevents adult card

31 mor suppressor (Lats1/2) core kinases of the Hippo pathway, a signaling pathway that plays important

32 her, our findings elucidate the mechanism of Hippo pathway activation by Merlin and Kibra, identify a

33 e evidence that YAP activity is repressed by Hippo pathway activation upon hepatocytic maturation in

34 These complexes are reorganized on Hippo pathway activation, when Warts shifts from associa

35 thus affects SMAD activation irrespective of Hippo pathway activation.

36 the regulatory protein Mob1, consistent with Hippo pathway activation.

37 ition signal, such as glucose, regulates the Hippo pathway activation.

38 Finally, we provide evidence that the Hippo pathway activity discriminates quiescent from non-

39 What controls Hippo pathway activity during cell fate specification is

40 Thus, AJUBA LIM proteins limit Hippo pathway activity in contexts where cell proliferat

41 insulator protein BEAF-32 as a regulator of Hippo pathway activity in Drosophila photoreceptor diffe

42 y identifies a context-specific regulator of Hippo pathway activity in post-mitotic neuronal fate, an

43 large protocadherin Fat functions to promote Hippo pathway activity in restricting tissue growth.

44 noid culture approaches, we demonstrate that Hippo pathway activity is essential for the maintenance

45 Whether and how Hippo pathway activity is limited to sustain or initiate

46 The Hippo pathway activity is modulated via inter-cellular t

47 e same or independent mechanisms to regulate Hippo pathway activity is not known.

48 as(V12) depends on its ability to counteract Hippo pathway activity, creating a positive feedback loo

49 links cytoskeletal tension to regulation of Hippo pathway activity, providing a molecular understand

50 ich is due at least in part to inhibition of Hippo pathway activity.

51 talk of ARF/beta-catenin dysregulated YAP in Hippo pathway and a new approach to stimulate ARF-mediat

52 cells leads to spontaneous activation of the Hippo pathway and alleviates the need for SAV1 in Hippo

53 herin, decreased Ajuba expression, increased Hippo pathway and caspase activation and apoptosis, and

54 he unknown interaction between the canonical Hippo pathway and cell tension.

55 a potential regulatory role of PTPN14 in the Hippo pathway and demonstrate another layer of regulatio

56 Understanding the regulation of the Hippo pathway and discovering upstream regulators is thu

57 Here we provide a brief overview of the Hippo pathway and discuss the physiological and patholog

58 irways maintain quiescence by activating the Hippo pathway and inhibiting Fgf10 expression in airway

59 Recently, the Hippo pathway and its transcriptional co-activator Yes-a

60 e data link transcriptional effectors of the Hippo pathway and of mechanotransduction to myelin forma

61 have shown evidence of crosstalk between the Hippo pathway and other key signaling pathways, such as

62 in 2 (or Merlin), a molecule upstream of the Hippo pathway and that is inactivated by protein kinase

63 eedback loop between the Warts kinase of the Hippo pathway and the PH-domain growth regulator Melted

64 ng epithelia to regulate tissue size via the Hippo pathway and tissue shape via modulating tension at

65 A sequence analysis showed activation of the Hippo pathway, and immunohistochemical and transcription

66 warts (wts), a tumor-suppressor gene in the Hippo pathway, and interacts with the Src oncogene.

67 AD interaction at the heart of the oncogenic Hippo pathway, and possessing the potency and stability

68 tein is an in vivo regulatory target of this hippo pathway, and predicts a new group of high-confiden

69 s a key negative regulator of YAP within the Hippo pathway, and we further show that cyclic stretch i

70 New and exciting studies of the Hippo pathway are anticipated that will significantly im

71 by a hierarchical model in which elements of Hippo pathway are under the control of focal adhesions (

72 "Hippo" pathways are ancient protein kinase signaling sys

73 TAZ and YAP (TAZ/YAP), key effectors of the Hippo pathway, are necessary to promote and maintain TGF

74 Recent studies have expanded the Hippo pathway as a complex signaling network with >30 co

75 Here, we define the Hippo pathway as a key mediator of hematopoiesis by show

76 ultiple model organisms have established the Hippo pathway as a key regulator of organ size and tissu

77 ostasis, and the well-documented role of the Hippo pathway as a tumor suppressor, these results repre

78 eam effector of the evolutionarily conserved Hippo pathway, as a central regulator for generating dev

79 be involved in cell polarity, migration, and Hippo pathway, as a component of the Cad11 protein compl

80 ned cell proliferation and activation of the Hippo pathway at elevated cell density.

81 sis by activating upstream components of the Hippo pathway at the plasma membrane or by inhibiting th

82 However, it is not well understood how the Hippo pathway becomes dysregulated because few mutations

83 that in these tumours, Sox2 antagonizes the Hippo pathway by direct repression of two Hippo activato

84 This negative regulation of the Hippo pathway by fibronectin adhesion signaling can, at

85 Yki), the transcriptional coactivator of the Hippo pathway, by inducing yki transcription.

86 is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide ap

87 activity between the mechanosensing and the Hippo pathways can be explained by the interaction of LI

88 cell death through its interaction with the Hippo pathway coactivator YAP1 in normal cells, we show

89 and bantam, that are classic targets of the Hippo pathway coactivator Yorkie.

90 We profiled Hippo pathway component expression in a panel of human m

91 Here we show that deletion of the Hippo pathway component Salvador (Salv) in mouse hearts

92 ession of yes associated protein 1 (YAP1), a Hippo pathway component that itself was associated with

93 all intestine or colon, deletion of upstream Hippo pathway components also results in expansion of in

94 verview of the functional importance of many Hippo pathway components and demonstrate NF2 and RHOA as

95 an cancer has remained enigmatic inasmuch as Hippo pathway components are rarely mutated in tumors.

96 s dysregulated because few mutations in core Hippo pathway components have been identified.

97 We report here that Hippo pathway components in Drosophila wing imaginal dis

98 ne the activity of YAP and the expression of Hippo pathway components in tumor and non-neoplastic liv

99 Multiple Hippo pathway components localize to apical junctions in

100 In the liver, knockout of upstream Hippo pathway components or transgenic expression of Yap

101 we show that PCBP2 forms a complex with the Hippo pathway components Salvador (Sav1), Mst1, Mst2, an

102 To provide an overview of important Hippo pathway components, we created knockout cell lines

103 The core of the Hippo pathway consists of a kinase cascade, transcriptio

104 Interestingly, while the core of the Hippo pathway contains a highly conserved kinase cascade

105 Whether the Hippo pathway contributes to cell lineage transition und

106 Here we report that the Hippo pathway controls liver cell lineage specification

107 The Hippo pathway controls organ growth and is implicated in

108 The Hippo pathway controls tissue growth and homeostasis thr

109 The Hippo pathway controls tissue growth through a core kina

110 Here, we show that the Notch and Hippo pathways converge to regulate smooth muscle differ

111 tivated protein, the progrowth target of the Hippo pathway core kinase cassette, both in flies and ma

112 is reduced tension modulates a biomechanical Hippo pathway, decreasing recruitment of Ajuba LIM prote

113 We show that Pix and Git regulate Hippo-pathway-dependent tissue growth in D. melanogaster

114 In the liver, Hippo pathway deregulation promotes hyperplasia and hepa

115 we show that YAP, the major effector of the Hippo pathway, displays a distinct activation pattern in

116 The Hippo pathway downstream kinase Warts, LATS1-2 in mammal

117 and Yorkie, transcriptional effectors of the Hippo pathway, drive Cyclin E expression to induce cell

118 rprisingly, activation of autophagy enhanced Hippo pathway-driven overgrowth in glia cells.

119 These data suggest that Hippo pathway dysfunction promotes RMS.

120 dermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ in human cancer cells.

121 in BRAF-mutant tumor cells, we show that the Hippo pathway effector YAP (encoded by YAP1) acts as a p

122 the pro-survival signaling of the downstream Hippo pathway effector YAP (Yes-associated protein) in D

123 required to regulate the localisation of the Hippo pathway effector YAP in response to cell density h

124 Here, we provide evidence that the Hippo pathway effector Yap is a key regulator of this pr

125 Here, we report that the Hippo pathway effector Yap promotes the diploid-polyploi

126 dystroglycan 1 (Dag1) directly binds to the Hippo pathway effector Yap to inhibit cardiomyocyte prol

127 PrP(c) also interacts with the Hippo pathway effector YAP, suggesting that it may contr

128 roteins, which are potent inhibitors for the Hippo pathway effector YAP.

129 t genes was cooperatively regulated with the Hippo pathway effector Yap.

130 ction in the LLP is mediated together by the Hippo pathway effector Yap1 and the Wnt/beta-catenin eff

131 RASSF1A degradation is necessary to permit Hippo pathway effector YAP1 association with SMADs and s

132 The role of the Hippo pathway effector YAP1 in soft tissue sarcomas is p

133 ed completely novel roles for Merlin and the Hippo pathway effector Yes-associated protein (YAP) in t

134 Hedgehog (Hh) signaling induces the Hippo pathway effector Yorkie (Yki) to promote prolifera

135 Here, we report that Yap, the Hippo pathway effector, is a chief player in this proces

136 nnectivity between the NF-kappaB pathway and Hippo pathway effectors at the transcriptional level, th

137 he cell density-mediated localization of the Hippo pathway effectors TAZ (transcriptional co-activato

138 We and others have shown that the Hippo pathway effectors TAZ and YAP direct Smad activity

139 first in-depth analysis of expression of the Hippo pathway effectors YAP (yes-associated protein) and

140 present study, "Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanom

141 Here, we show that the Hippo pathway effectors YAP and TAZ work as crucial sign

142 eficient in epicardial YAP and TAZ, two core Hippo pathway effectors, developed profound post-MI peri

143 eptor tyrosine kinase c-Src and recruits the Hippo pathway effectors, Yap (yes-associated protein) an

144 The Hippo pathway, evolutionarily conserved from flies to ma

145 Dysregulation of the Hippo pathway exerts a significant impact on cancer deve

146 sphorylation, revealing a connection between Hippo pathway function and the DGC.

147 Aberrant Hippo pathway function is often detected in human cancer

148 -NRG1 fusion and suggests that NRG1, NF1 and Hippo pathway fusions may play important roles in tumour

149 Thus, the Salvador-Warts-Hippo pathway has a cell-autonomous function to prevent

150 The repressive Hippo pathway has a profound tumour suppressive role in

151 The function of the Hippo pathway has also been studied in other gastrointes

152 The Hippo pathway has an important role in organ size contro

153 The Yes-associated protein (YAP)/Hippo pathway has been implicated in tissue development,

154 Whether the Hippo pathway has downstream targets other than YAP and

155 2), two sets of upstream core kinases of the Hippo pathway, has no effect in blocking netrin-1-induce

156 The major functions of the Hippo pathway have been defined to restrict tissue growt

157 Diverse roles for the Hippo pathway have emerged, the majority of which in ver

158 evidence of cross-talk between the mTOR and Hippo pathways; however, a complete description of the s

159 o constitute a negative feedback loop of the Hippo pathway in both cultured cells and mouse tissues.

160 Little is known about the status of the Hippo pathway in cutaneous melanoma.

161 s not noticeably impair the functions of the Hippo pathway in eye growth regulation.

162 bes how a palmitoyltransferase regulates the Hippo pathway in flies.

163 These findings support the importance of the Hippo pathway in hemangioendothelioma cell proliferation

164 involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids m

165 Our study establishes a pivotal role of the Hippo pathway in mediating the oncogenic activity of KSH

166 Our observations uncover a key role of the Hippo pathway in modulating tumor immunogenicity and dem

167 e describe a previously unknown role for the Hippo pathway in myelination.

168 between nephrin signaling and the canonical Hippo pathway in podocytes, which may facilitate the con

169 The activity state of the Hippo pathway in R8 cells is determined by the expressio

170 Cell, two groups find critical roles for the Hippo pathway in regulation of lung progenitor cell diff

171 Our results implicate for the first time the Hippo pathway in size regulation in the LL system.

172 ere, we discovered an unexpected role of the Hippo pathway in suppressing anti-tumor immunity.

173 Drosophila, does not apparently regulate the Hippo pathway in the murine liver.

174 tion molecule modulation of survivin and the Hippo pathway in the proliferation and apoptosis of a mu

175 Hippo pathway inactivation disrupts the asymmetric local

176 Core components of the Hippo pathway include a kinase cascade of MST1/2 and LAT

177 YAP1 encodes an effector of the HIPPO-pathway-induced growth response, and whole-mount i

178 Our study indicates that Hippo pathway inhibition is required for the increased m

179 At high cell density, the Hippo pathway inhibits DNA damage-induced c-Abl activati

180 protein (YAP), the terminal effector of the Hippo pathway, interacts with FoxO1 in the nucleus of ca

181 the Yes-associated protein 1, is part of the Hippo pathway involved in development, growth, repair an

182 nscriptional co-activators downstream of the Hippo pathway involved in the regulation of organ size,

183 The Hippo pathway is a conserved signaling cascade that modu

184 In this model, the Yap protein of the Hippo pathway is activated in the eyes, and blood vessel

185 The Hippo pathway is an evolutionarily conserved regulator o

186 The Hippo pathway is an evolutionarily conserved signaling p

187 The Hippo pathway is an important organ size control signali

188 Here we show that the Hippo pathway is critical for this decision.

189 The Hippo pathway is crucial for not only normal growth and

190 The Hippo pathway is crucial in organ size control and tissu

191 Here we report that that the Hippo pathway is deregulated in many soft-tissue sarcoma

192 Since the Hippo pathway is deregulated in various cancers, designi

193 Here, we found that the Hippo pathway is directly regulated by the hexosamine bi

194 The Hippo pathway is emerging as a key evolutionarily conser

195 The Hippo pathway is important for regulating tissue homeost

196 However, whether the regulation of the Hippo pathway is indeed different between Drosophila and

197 The Hippo pathway is involved in the regulation of contact i

198 The Hippo pathway is known for its role in controlling organ

199 In epithelial tissues, the Hippo pathway is regulated by fundamental cell biologica

200 Induction of the Hippo pathway is triggered in part by extra centrosomes,

201 tion of PCP in mammals but the link with the Hippo pathway is unclear.

202 The Salvador-Warts-Hippo (Hippo) pathway is a conserved regulator of organ size an

203 The Salvador-Warts-Hippo (Hippo) pathway is an evolutionarily conserved regulator

204 tein 1 (YAP1), a key nuclear effector of the Hippo pathway, is a potent oncogene, and yet, the intera

205 ng pathway, also known as the Salvador-Warts-Hippo pathway, is a regulator of organ size.

206 o-factor that is negatively regulated by the Hippo pathway, is crucial for the development and size c

207 ptional regulator Yap, a key effector of the Hippo pathway, is required for the proper patterning and

208 found that Yap, a downstream effector of the Hippo pathway, is specifically expressed in these stem c

209 demonstrate that YAP activity decreases and Hippo pathway kinase activities increase upon differenti

210 The Hippo pathway kinase Lats1/2 (large tumor suppressor hom

211 t extra centrosome-induced activation of the Hippo pathway kinase LATS2 is a key mechanism of tetrapl

212 Mad and dSmad2 cooperate to modulate the Hippo pathway kinase Warts and the growth regulator Melt

213 ing recruitment of Ajuba LIM protein and the Hippo pathway kinase Warts, and decreasing the activity

214 In animals lacking the downstream Hippo pathway kinase Warts, lymph gland cells overprolif

215 PDK1 associates with the core Hippo pathway-kinase complex through the scaffold protei

216 mor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1

217 promotes the interaction between Yap and the Hippo pathway kinases Lats1/2 at apical cell junctions t

218 acts through Gq/11 and G12/13 to inhibit the Hippo pathway kinases Lats1/2, promoting the activation

219 Furthermore, dysregulation of the Hippo pathway leads to aberrant cell growth and neoplasi

220 The hippo pathway leads to phosphorylation of the transcript

221 An EGFR-Hippo pathway link is conserved in mammals, as activatio

222 Thus, the Hippo pathway links contact-inhibition regulation to miR

223 ed on these data we propose that NF2 and the Hippo pathway locally repress YAP/TAZ activity in the UB

224 In the adult liver, the Hippo pathway mammalian STE20-like protein kinases 1 and

225 Other upstream regulators of the Hippo pathway mediate this effect of Yki on retinal diff

226 In this report, we show that the Hippo pathway mediates GGylation-dependent cell prolifer

227 is a nuclear co-factor of FoxO1 and that the Hippo pathway negatively affects cardiomyocyte survival

228 to Merlin degradation, downregulation of the Hippo pathway, nuclear Yap translocation, and expression

229 rotein, YAP, is a downstream effector of the Hippo pathway of cell-cycle control that plays important

230 suppressing activation of the Salvador-Warts-Hippo pathway of tumor suppressors, activation that requ

231 Inactivation of the Hippo pathway or expression of constitutively active YAP

232 ession of PAR1, an upstream regulator of the Hippo pathway; PAR1 promotes invasion, migration, and CS

233 The Hippo pathway plays a central role in tissue homoeostasi

234 The Hippo pathway plays a critical role in organ size contro

235 The Hippo pathway plays a crucial role in regulating tissue

236 The Hippo pathway plays a key role in controlling organ grow

237 The Hippo pathway plays essential roles in organ size contro

238 inases (LATS) 1 and 2, which are part of the Hippo pathway, promotes the luminal phenotype and increa

239 ivo and suggest that Ctp may interact with a Hippo pathway protein(s) to exert inverse transcriptiona

240 The Hippo pathway regulated crystal cell numbers by both cel

241 The hippo pathway-regulated cofactor YAP1 supports the tumor

242 YAP and TAZ transcription co-activators, the Hippo pathway regulates cell proliferation, apoptosis, a

243 Here we reveal that the Hippo pathway regulates the expansion of DRG progenitors

244 The Hippo pathway regulates the self-renewal and differentia

245 The Hippo pathway regulates the transcriptional coactivator

246 and Kibra, identify a subcellular domain for Hippo pathway regulation, and demonstrate differential a

247 ficant implications for our understanding of Hippo pathway regulation, YAP-isoform specific signaling

248 the mouse Fat4 cadherin, the ortholog of the Hippo pathway regulator Fat in Drosophila, does not appa

249 ivation via a previously unappreciated FSTL5-Hippo pathway regulatory axis.

250 o the other known upstream regulators of the Hippo pathway remains poorly defined.

251 Despite rapid advances in Hippo pathway research, a definitive role for this pathw

252 their stem cell state by downregulating the Hippo pathway (resulting in increased nuclear Yap), whic

253 nterference with the YAP-TEAD complex of the HIPPO pathway, resulting in growth inhibition of several

254 ization, consistent with inactivation of the Hippo pathway, resulting in increased proliferation and

255 Epigenetic inactivation of the Hippo pathway scaffold RASSF1A is associated with poor p

256 Here, we investigated the functions of the Hippo pathway serine/threonine-protein kinases Lats1 and

257 -mediated transformation and maintain active hippo pathway signaling compared to wild-type cells or c

258 Remarkably, acute inactivation of Hippo pathway signaling in vivo is sufficient to dediffe

259 vin and Ajuba expression, and a reduction in Hippo pathway signaling resulting in increased prolifera

260 We recently documented an important role for Hippo pathway signaling via endothelial cell adhesion mo

261 enocopied the effects of Setd7 deficiency on Hippo pathway signaling, via modulation of the transcrip

262 of YAP as well as chemical inhibitors of the Hippo pathway such as S1P recover the ER instability and

263 This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a pro

264 discs leads to pathogenic activation of the Hippo pathway, suppression of the canonical Wnt signalin

265 ses to restrain Rho GTPase activity, support Hippo pathway suppressor functions, and restrain prostat

266 kidneys associated with the upregulation of Hippo pathway target genes and marker genes of TGF-beta

267 We also found that the downstream Hippo pathway target Yes-associated protein 1 (YAP), whi

268 The Hippo pathway targets YAP1 for degradation via the betaT

269 and proliferation in part by activating the Hippo pathway that drives the phosphorylation and nuclea

270 motif) are major downstream effectors of the Hippo pathway that influences tissue homeostasis, organ

271 Yap and Taz are effectors of the Hippo pathway that integrate chemical and mechanical sig

272 n this review, we present an overview of the Hippo pathway, the sequence and structural analysis of Y

273 We find that two components of the Hippo pathway, the tumor suppressor Nf2 (Merlin) and the

274 athways shows that EGF receptor inhibits the Hippo pathway through activation of PI3-kinase (PI3K) an

275 Therefore, these results link the Hippo pathway to EGFR-mediated renal epithelial injury i

276 oN interacts with multiple components of the Hippo pathway to inhibit the binding of Lats2 to TAZ and

277 Sox2 interferes with the tumour-suppressive Hippo pathway to maintain CSCs in osteosarcomas.

278 protein Amot130 scaffolds components of the Hippo pathway to promote the inhibition of cell growth.

279 n effector that transduces the output of the Hippo pathway to transcriptional modulation.

280 , a transcription coactivator that binds the Hippo pathway transcription factor YAP/TAZ, contributes

281 XC2-dependent quiescence was mediated by the Hippo pathway transcriptional coactivator TAZ and, ultim

282 Hippo pathway transcriptional coactivators TAZ and YAP a

283 We show that the Hippo pathway transcriptional coactivators Yap1 and Wwtr

284 RASSF1A reduced nuclear accumulation of the Hippo pathway transcriptional cofactor Yes-associated pr

285 Our results reveal how the Hippo pathway transcriptional program, localized to two

286 though decreased autophagy did not influence Hippo pathway-triggered overgrowth, activation of autoph

287 and tumorigenesis through inhibition of the Hippo pathway tumor suppressor MST1.

288 Loss of Hippo pathway tumor suppressors or activation of Yorkie

289 iquitin ligases that negatively regulate the Hippo pathway via ubiquitination, yet few deubiquitinati

290 The Hippo pathway was initially identified in Drosophila mel

291 ned novel domains that connected them to the Hippo pathway, whereas the cell-adhesion receptor Echino

292 a downstream nuclear transcription factor of Hippo pathway which plays an essential role in developme

293 echanism by which cell density activates the Hippo pathway, which in turn inactivates YAP, leading to

294 ear to have an important role along with the Hippo pathway, which may integrate multiple types of inp

295 tor, is the major downstream effector of the Hippo pathway, which plays a critical role in organ size

296 ated protein (YAP) is a core effector of the Hippo pathway, which regulates proliferation and apoptos

297 ciated protein (YAP), the main target of the Hippo pathway, which results in decreased expression of

298 Mechanistically, the core component of Hippo pathway (YAP) is O-GlcNAcylated by O-GlcNAc transf

299 c duct (ND) lineage the two effectors of the Hippo pathway, Yap and Taz.

300 ng adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcri